The utility of cold-preserved human hepatocytes in studies on cytochrome P450 induction and hepatic drug transport

References

• Alexandre E, Viollon-Abadie C, David P, et al. (2002). Cryopreservation of adult human hepatocytes obtained from resected liver biopsies. Cryobiology 44:103–13
   PubMed Web of Science ®Google Scholar
• Badolo L, Trancart MM, Gustavsson L, Chesne C. (2011). Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes. Chem Biol Interact 190:165–70
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). Pharmaceutical research and manufacturers of America drug metabolism/clinical pharmacology technical working groups. The conduct of in vitro and in vivo drug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–69
   PubMed Web of Science ®Google Scholar
• Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233–46
   PubMed Web of Science ®Google Scholar
• Chu V, Einolf HJ, Evers R, et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339–54
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell JV. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153–78
   PubMed Web of Science ®Google Scholar
• Floby E, Johansson J, Hoogstraate J, et al. (2009). Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 39:656–62
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJ, Houston JB, et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, et al. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793–806
   PubMed Web of Science ®Google Scholar
• Kamiguchi N, Aoyama E, Okuda T, Moriwaki T. (2010). A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes. Drug Metab Dispos 38:1912–16
   PubMed Web of Science ®Google Scholar
• Kostrubsky VE, Ramachandran V, Venkataramanan R, et al. (1999). The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887–94
   PubMed Web of Science ®Google Scholar
• LeCluyse E, Madan A, Hamilton G, et al. (2000). Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177–88
   PubMed Web of Science ®Google Scholar
• Li AP, Lu C, Brent JA, et al. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 121:17–35
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. (2011). Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575–81
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247–53
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Zhang G, Kenny JR, et al. (2009). Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259–68
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Haruta T, Shirasaka Y, Tamai I. (2011). Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos 39:117–22
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. (2003). Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580–8
   PubMed Web of Science ®Google Scholar
• Ozawa N, Shimizu T, Morita R, et al. (2004). Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm Res 21:2133–4
   PubMed Web of Science ®Google Scholar
• Palmgren A-P, Fihn B-M, Bird J, et al. (2012). A novel matrix for the short term maintenance of cellular function: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes. Xenobiotica, epub ahead of print, doi:10.3109/00498254.2012.738316
   PubMed Web of Science ®Google Scholar
• Richert L, Abadie C, Bonet A, et al. (2010). Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers – a European Centre for Validation of Alternative Methods (ECVAM) – funded pre-validation study. Toxicol In Vitro 24:335–45
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Sinz M, Wallace G, Sahi J. (2008). Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, Grime K, Riley RJ. (2007). The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2–15
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637–49
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K, Schmidt S. (2005). Impaired glutathione-conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica 35:727–36
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Hausler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400–7
   PubMed Web of Science ®Google Scholar
• Ulvestad M, Bjorquist P, Molden E, et al. (2011). OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochem Pharmacol 82:1219–26
   PubMed Web of Science ®Google Scholar
• Walsky RL, Boldt SE. (2008). In vitro cytochrome P450 inhibition and induction. Curr Drug Metab 9:928–39
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. (2001). Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 1:403–25
   PubMedGoogle Scholar